{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:25:59Z","timestamp":1793496359163,"version":"4.5.0"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder often associated with metabolic disturbances such as insulin resistance and metabolic syndrome (MetS). Visceral adiposity index (VAI) is a validated marker that reflects visceral fat distribution and cardiometabolic risk. This study aimed to compare VAI levels among different PCOS phenotypes to evaluate cardiometabolic risk across these phenotypes. Materials and Methods: This prospective case\u2013control study included 180 PCOS patients and 51 healthy controls without any metabolic or reproductive issues. Patients were divided into the following subtypes based on the Rotterdam criteria: Phenotype A (n = 96), clinical and\/or biochemical hyperandrogenism (HA) + oligo-anovulation (OA) + polycystic ovarian morphology (PCOM); Phenotype B (n = 19), HA + OA; Phenotype C (n = 35), HA + PCOM; and Phenotype D (n = 30), OA + PCOM. VAI was calculated for women using anthropometric and biochemical parameters. Results: In the total PCOS group, VAI levels were significantly higher than in controls (p &lt; 0.001). Phenotypes A and B had higher VAI values than controls and also higher in Phenotype A than in Phenotypes C and D (p = 0.003 and p = 0.001, respectively). While present in 38 patients (21.10%) in the PCOS group, there was no metabolic syndrome (MetS) in controls (p &lt; 0.001). In Phenotypes A, B, and D, while more patients had MetS than controls (p &lt; 0.001, 0.004, and 0.021, respectively), more patients had MetS in Phenotype A compared to Phenotypes C and D (p = 0.003 and p = 0.021, respectively). Given ROC analysis, the VAI cut-off value in predicting MetS in the PCOS group was 1.66 (sensitivity = 94.74% and specificity = 83.10%). Conclusions: PCOS phenotypes characterized by HA and OA, particularly Phenotypes A and B, are associated with higher VAI values and an increased frequency of MetS risk. Early identification of these phenotypes may facilitate the implementation of targeted metabolic risk reduction and early intervention strategies, thereby contributing to the reduction of cardiovascular risk.<\/jats:p>","DOI":"10.3390\/medicina61091673","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T10:51:33Z","timestamp":1757933493000},"page":"1673","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Visceral Adiposity Index (VAI) Levels and Metabolic Risk Across Phenotypes of Polycystic Ovary Syndrome (PCOS)"],"prefix":"10.3390","volume":"61","author":[{"given":"Canan","family":"Akkus","sequence":"first","affiliation":[{"name":"The Department of Internal Medicine, The Medical School of Usak University, Usak 64300, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oznur","family":"Oner","sequence":"additional","affiliation":[{"name":"The Department of Obstetrics and Gynecology, The Medical School of Usak University, Usak 64300, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8005-5084","authenticated-orcid":false,"given":"Atilla Okan","family":"Kilic","sequence":"additional","affiliation":[{"name":"The Department of Internal Medicine, The Division of Endocrinology and Metabolism, The Medical School of Usak University, Usak 64300, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevdet","family":"Duran","sequence":"additional","affiliation":[{"name":"The Department of Internal Medicine, The Division of Endocrinology and Metabolism, The Medical School of Usak University, Usak 64300, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J.S., Legro, R.S., Lizneva, D., Natterson-Horowtiz, B., Teede, H.J., and Yildiz, B.O. (2016). Polycystic ovary syndrome. Nat. Rev. Dis. Primers, 2.","DOI":"10.1038\/nrdp.2016.57"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod., 19, 41\u201347.","DOI":"10.1093\/humrep\/deh098"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E1967","DOI":"10.1210\/jc.2013-2815","article-title":"The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS","volume":"98","author":"Brower","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.fertnstert.2008.06.021","article-title":"Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS","volume":"92","author":"Landay","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/0002-8703(94)90073-6","article-title":"Syndrome X: Is one enough?","volume":"127","author":"Reaven","year":"1994","journal-title":"Am. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rojas, J., Chavez, M., Olivar, L., Rojas, M., Morillo, J., Mejias, J., Calvo, M., and Bermudez, V. (2014). Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth. Int. J. Reprod. Med., 2014.","DOI":"10.1155\/2014\/719050"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications","volume":"33","author":"Dunaif","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_8","unstructured":"Azziz, R. (2020, August 18). Epidemiology, Phenotype, and Genetics of the Polycystic Ovary Syndrome in Adults. Available online: https:\/\/www.uptodate.com\/contents\/epidemiology-phenotype-and-genetics-of-the-polycystic-ovary-syndrome-in-adults?search=polycystic%20ovarian%20syndrome%20subtype&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3349\/ymj.2013.54.3.609","article-title":"Is insulin resistance an intrinsic defect in asian polycystic ovary syndrome?","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/humupd\/dms030","article-title":"Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis","volume":"18","author":"Lim","year":"2012","journal-title":"Hum. Reprod. Update"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/eurheartj\/ehn573","article-title":"Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: The Framingham Heart Study","volume":"30","author":"Mahabadi","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2012.01053.x","article-title":"The effect of obesity on polycystic ovary syndrome: A systematic review and meta-analysis","volume":"14","author":"Lim","year":"2013","journal-title":"Obes. Rev. An. Off. J. Int. Assoc. Study Obes."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/aogs.12964","article-title":"Comparison of regional fat mass measurement by whole body DXA-scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls","volume":"95","author":"Glintborg","year":"2016","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_14","first-page":"893","article-title":"Adipose tissue determinations in cadavers--a comparison between cross-sectional planimetry and computed tomography","volume":"14","author":"Rossner","year":"1990","journal-title":"Int. J. Obes."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1177\/1932296815577424","article-title":"Does Visceral Fat Estimated by Dual-Energy X-ray Absorptiometry Independently Predict Cardiometabolic Risks in Adults?","volume":"9","author":"Sasai","year":"2015","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Amato, M.C., and Giordano, C. (2014). Visceral adiposity index: An indicator of adipose tissue dysfunction. Int. J. Endocrinol., 2014.","DOI":"10.1155\/2014\/730827"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/humrep\/det105","article-title":"Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): A comparative analysis of four simple methods useful for metabolic assessment","volume":"28","author":"Amato","year":"2013","journal-title":"Hum. Reprod."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000446121","article-title":"Visceral Adiposity Index Is Associated with Pre-Diabetes and Type 2 Diabetes Mellitus in Chinese Adults Aged 20-50","volume":"68","author":"Liu","year":"2016","journal-title":"Ann. Nutr. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1590\/1516-3180.2015.01452111","article-title":"Visceral adiposity index and prognosis among patients with ischemic heart failure","volume":"134","author":"Vogel","year":"2016","journal-title":"Sao Paulo Med. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40618-016-0582-x","article-title":"Visceral adiposity index levels in overweight and\/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters","volume":"40","author":"Durmus","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ganie, M.A., Malhotra, N., Jabbar, P.K., Aggarwal, S., Rozati, R., Sahay, R., Chowdhary, S., Kamboj, S., Wani, I.A., and Arora, T. (2025). Cardiometabolic markers and serum amh levels in PCOS: Can AMH serve as a surrogate cardiometabolic markeR?. BMC Women\u2019s Health, 25.","DOI":"10.1186\/s12905-025-03617-2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/humupd\/dmaa029","article-title":"Long-term cardiometabolic disease risk in women with PCOS: A systematic review and meta-analysis","volume":"26","author":"Wekker","year":"2020","journal-title":"Human Reprod. Update"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jogc.2018.11.026","article-title":"Comprehensive evaluation of type 2 diabetes and cardiovascular disease risk profiles in reproductive-age women with polycystic ovary syndrome: A large Canadian cohort","volume":"41","author":"Kazemi","year":"2019","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program (2001). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"ref_26","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/humrep\/den211","article-title":"Obesity, body composition and metabolic disturbances in polycystic ovary syndrome","volume":"23","author":"Svendsen","year":"2008","journal-title":"Hum. Reprod."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1024\/0300-9831\/a000691","article-title":"The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review","volume":"92","author":"Menichini","year":"2020","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.36129\/jog.2022.40","article-title":"Inositols administration: Further insights on their biological role","volume":"35","author":"Coldebella","year":"2023","journal-title":"Ital. J. Gynaecol. Obstet."},{"key":"ref_30","first-page":"1241","article-title":"Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?","volume":"26","author":"Monti","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/humrep\/der088","article-title":"The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: A likely condition of cardiometabolic risk","volume":"26","author":"Amato","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41366-024-01517-3","article-title":"Visceral-to-peripheral adiposity ratio: A critical determinant of sex and ethnic differences in cardiovascular risks among Asian Indians and African Creoles in Mauritius","volume":"48","author":"Ramessur","year":"2024","journal-title":"Int. J. Obes."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/ijem.IJEM_559_18","article-title":"Visceral adiposity index: Simple tool for assessing cardiometabolic risk in women with polycystic ovary syndrome","volume":"23","author":"Agrawal","year":"2019","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vale-Fernandes, E., Moreira, M.V., Bernardino, R.L., Sousa, D., Brand\u00e3o, R., Leal, C., Barreiro, M., and Monteiro, M.P. (2025). Polycystic ovary syndrome and excessive body weight impact independently and synergically on fertility treatment outcomes. Reprod. Biol. Endocrinol., 23.","DOI":"10.1186\/s12958-025-01434-8"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/EJE-14-0094","article-title":"Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: A population-based study","volume":"171","author":"Minooee","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Reyes-Farias, M., Fos-Domenech, J., Serra, D., Herrero, L., and Sanchez-Infantes, D. (2021). White adipose tissue dysfunction in obesity and aging. Biochem. Pharmacol., 192.","DOI":"10.1016\/j.bcp.2021.114723"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Amato, M.C., Giordano, C., Pitrone, M., and Galluzzo, A. (2011). Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis., 10.","DOI":"10.1186\/1476-511X-10-183"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/jhrs.jhrs_14_24","article-title":"Utility of Visceral Adiposity Index and Lipid Accumulation Products to Define Metabolically-Unhealthy Polycystic Ovary Syndrome in Asian Indian Women-A Cross Sectional Study","volume":"17","author":"Shreenidhi","year":"2024","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0042-119524","article-title":"Adiposity indexes as phenotype-specific markers of preclinical metabolic alterations and cardiovascular risk in polycystic ovary syndrome: A cross-sectional study","volume":"125","author":"Mario","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/jhrs.jhrs_114_21","article-title":"Lipid accumulation product better predicts metabolic status in lean polycystic ovary syndrome than that by visceral adiposity index","volume":"15","author":"Banu","year":"2022","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_41","unstructured":"Hunter, G.R., Gower, B.A., and Kane, B.L. (2010). Age related shift in visceral fat. Int. J. Body Compos. Res., 8."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sun, Q., Wang, S., Han, X., Gu, L., Wang, H., Yang, Q., and Wang, L. (2025). The association between visceral adiposity index and long-term all-cause mortality shows age-related disparities: A nationwide cohort study. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-22428-6"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1673\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:45Z","timestamp":1760035545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091673"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091673","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}